Oestrogen and vascular disease

Australian and New Zealand Journal of Medicine

Volumn 29, Issue 3, 1999, Pages 473-479

  Harvey, P ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Cardioprotection; Cardiovascular disease; Hormone replacement therapy; Menopause; Oestrogen; Progestogen

Indexed keywords

ESTROGEN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; ESTROGEN ACTIVITY; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FIBRINOLYSIS; HEART PROTECTION; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; MENOPAUSE; POSTMENOPAUSE; VASODILATATION;

EID: 0033037409     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1999.tb00745.x     Document Type: Conference Paper

References (43)

1. 1. Manhem K. Cardiovascular risk in postmenopausal women: What is known and what is unknown? In: Safar M, Stimpel M, Zanchetti A (Eds). Hypertension in postmenopausal women. Berlin, Heidelberg: Springer-Verlag, 1994: 3-14.
2. 2. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med 1995; 332: 1758-66.
3. 3. Grady D, Rubin S, Petitti D et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37.
4. 4. Harlap S. The benefits and risks of hormone replacement therapy: an epidemiologic review. Am J Obstet Gynecol 1995; 166: 1986-92.
5. 5. Barrett-Connor E. Estrogen and estrogen-progestogen replacement: therapy and cardiovascular diseases. Am J Med 1993; 95 (Suppl. 5A): 40S-43S.
6. 6. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985; 313: 1044-9.
7. 7. Bush TL, Barrett-Connor E, Cowan LD et al. Cardiovascular mortality and contraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75: 1102-9.
8. 8. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991; 151: 75-8.
9. 9. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ 1988; 297: 519-22.
10. 10. Manson JE, Tosteson H, Satterfield S, Hebert P, O'Connor GT, Hennekens CH. The primary prevention of myocardial infarction. N Engl J Med 1992; 326: 1406-15.
11. 11. Posthuma WFM, Westendorp RGJ, Vandenbroucke JP. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ 1994; 308: 1268-9.
12. 12. Wilson PWF, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking and cardiovascular morbidity in women over 50. The Framingham Study. N Engl J Med 1985; 313: 1038-43.
13. 13. Stampfer MJ, Colditz GA, Willett WC et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991; 325: 756-62.
14. 14. Grodstein F, Stampfer MJ, Colditz GA et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769-75.
15. 15. Stampfer M, Grodstein F. Cardioprotective effect of hormone replacement therapy. Is not due to a selection bias. BMJ 1994; 309: 808-9.
16. 16. Colditz GA, Willett WC, Stampfer MJ, Rosher B, Speizer FF, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987; 316: 1105-10.
17. 17. Lindsay D. Association of hormone replacement therapy with cardiovascular disease risk factors in postmenopausal women. Cardiology 1994; 13: 35-40.
18. 18. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199-208.
19. 19. Nabulsi AA, Folsom AR, White A et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069-75.
20. 20. Gotto AM, Jr. Postmenopausal hormone-replacement therapy, plasma lipoprotein[a], and risk for coronary heart disease. J Lab Clin Med 1994; 123: 800-3.
21. 21. Bruckert E, Turpin G. Estrogens and progestins in postmenopausal women: Influence on lipid parameters and cardiovascular risk. Horm Res 1995; 43: 100-3.
22. 22. Kim C, Jang H, Cho D, Min Y. Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb 1994; 14: 275-81.
23. 23. Staessen JA, Bulpitt CJ, Fagard R, Lijnen P, Amery A. The influence of menopause on blood pressure. In: Safar M, Stimpel M, Zanchetti A (Eds). Hypertension in postmenopausal women. Berlin, Heidelberg: Springer-Verlag, 1994: 15-26.
24. 24. Lindquist O. Intra-individual changes of blood-pressure, serum lipids and body weight in relation to menstrual status: results from a prospective population study in Goteborg, Sweden. Prev Med 1982; 11: 162-72.
25. 25. Lobo RA. Estrogen replacement therapy and hypertension. Postgrad Med 1987; 14: 48-54.
26. 26. Wren BG, Brown LB, Routledge DA. Differential clinical response to oestrogens after menopause. Med J Aust 1982; 2: 329-32.
27. 27. Lobo RA, Pickar JH, Wild RA, Walsh B, Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obset Gynecol 1994; 84: 987-95.
28. 28. Gebara OCE. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91: 1952-8.
29. 29. Daly E, Vessey MP, Hawkins MM et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.
30. 30. Jick H, Derby LE, Myers MW et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-3.
31. 31. Grodstein F, Stampfer MJ, Goldhaber SZ et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-7.
32. 32. Pines A, Fisman EZ, Ayalon D, Drory Y, Averbuch M, Levo Y. Long-term effects of hormone replacement therapy on Doppler-derived parameters of aortic flow in postmenopausal women. Chest 1992; 102: 1496-8.
33. 33. Pines A, Fisman EZ, Drory Y et al. Menopause-induced changes in Doppler-derived parameters of aortic flow in healthy women. Am J Cardiol 1992; 69: 1104-6.
34. 34. Collins P, Shay J, Jiang C, Moss J. Nitric oxide accounts for the dose-dependent estrogen-mediated coronary relaxion after acute estrogen withdrawal. Circulation 1994; 90: 1964-8.
35. 35. Collins P, Rosano GMC, Jiang C, Lindsay D, Sarrel PM, Poole-Wilson PA. Cardiovascular protection by oestrogen-a calcium antagonist effect? Lancet 1993; 341: 1264-5.
36. 36. Gilligan DM, Quyyumi AA, Cannon RO, III, Johnson GB, Schenke WH. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994; 89: 2545-51.
37. 37. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994; 90: 786-91.
38. 38. Chang W, Nako J, Orimo H, Muroto S. Stimulation of prostacyclin biosynthetic activity by estradiol in rat aortic smooth muscle cells in culture. Biochem Biophys Acta 1980; 619: 107-18.
39. 39. Bell DR, Rensberger HJ, Koritnik DR, Koshy A. Estrogen pretreatment directly potentiates endothelium-dependent vasorelaxation of porcine coronary arteries. Am J Physiol 1995; 268: 3773-83.
40. 40. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 1994; 91: 5212-6.
41. 41. Adams MR, Clarkson TB, Koritnik DR, Nash HA. Contraceptive steroids and coronary artery atherosclerosis in cynomolgus macaques. Fertil Steril 1987; 47: 1010-8.
42. 42. Schnaper HW, McGowan KA, Seunghee K, Cid MC. Oestrogen and endothelial cell angiogenic activity. Clin Exp Pharmacol Physiol 1996; 23: 247-50.
43. 43. Pines A, Fisman EZ, Levo Y et al. The effects of hormone replacement therapy in normal postmenopausal women: measurements of Doppler-derived parameters of aortic flow. Am J Obstet Gynecol 1991; 164: 806-12.